Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 10/20 | 0.46 |
| ▸ | GAA | P10253 | 10/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.46 |
| ▸ | MEN1 | O00255 | 8/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | GFER | P55789 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9529534 | 0.77 | HTT (0.48) | MAPTKMT2AMEN1SMN1; SMN2RAB9A | |
| Sulfuric Acid SCHEMBL8745492 | 0.72 | ACP1 (0.44) | NOX1MAPTGAAKMT2AMEN1 | |
| SCHEMBL9841099 | 0.72 | ACP1 (0.44) | NOX1MAPTGAAKMT2AMEN1 | |
| SCHEMBL1062674 | 0.71 | NOX1 (0.52) | NOX1MAPTGAAKMT2AMEN1 | |
| SCHEMBL6420581 | 0.71 | NOX1 (0.52) | NOX1MAPTGAAKMT2AMEN1 | |
| SCHEMBL16111932 | 0.71 | NOX1 (0.62) | NOX1MAPTGAAKMT2AMEN1 | |
| SCHEMBL13109406 | 0.71 | NOX1 (0.62) | NOX1MAPTGAAKMT2AMEN1 | |
| SCHEMBL16111930 | 0.71 | NOX1 (0.62) | NOX1MAPTGAAKMT2AMEN1 | |
| SCHEMBL11023309 | 0.71 | MEN1 (0.43) | NOX1MAPTGAAKMT2AMEN1 | |
| SCHEMBL14294534 | 0.68 | NOX1 (0.54) | NOX1MAPTGAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199129-B2 | Derivatives of morphine-like opioid compounds | MONASH UNIVERSITY (AU) | 2007-04-03 | — | — | US | disclosed |
| EP-1423392-B1 | DERIVATIVES OF MORPHINE-LIKE OPIOID COMPOUNDS | NEURO THERAPEUTICS LTD (AU) | 2006-10-04 | — | — | EP | disclosed |
| US-20040242616-A1 | Derivatives of morphine-like opioid compounds | NEURO THERAPEUTICS LIMITED (AU) | 2004-12-02 | — | — | US | disclosed |
| EP-1423392-A4 | DERIVATIVES OF MORPHINE-LIKE OPIOID COMPOUNDS | POLYCHIP PHARMACEUTICALS PTY (AU) | 2004-11-17 | — | — | EP | disclosed |
| EP-1423392-A1 | DERIVATIVES OF MORPHINE-LIKE OPIOID COMPOUNDS | Polychip Pharmaceuticals Pty. Ltd. (AU) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003014122-A1 | DERIVATIVES OF MORPHINE-LIKE OPIOID COMPOUNDS | POLYCHIP PHARMACEUTICALS PTY LTD (AU) | 2003-02-20 | — | — | WO | disclosed |
| US-5998399-A | Guanidine derivatives useful in therapy as inhibitors of nitric oxide synthetase | ASTRA AKTIEBOLAG (SE) | 1999-12-07 | — | — | US | disclosed |
| US-5908863-A | ANTIGROWTH AGENT FOR BONES | DOMPE' S.P.A. (IT) | 1999-06-01 | — | — | US | disclosed |
| EP-0690851-B1 | GUANIDINE DERIVATIVES USEFUL IN THERAPY | ASTRA AB (SE) | 1999-05-19 | — | — | EP | disclosed |
| US-5885985-A | Guanidine derivatives useful in therapy | ASTRA AKTIEBOLAG (SE) | 1999-03-23 | — | — | US | disclosed |
| EP-0792878-A2 | Geminal carboxylic acids and esters thereof, pharmaceutical formulations containing them useful in the treatment of bone dysmetabolism | Dompé S.P.A. (IT) | 1997-09-03 | — | — | EP | disclosed |
| EP-0690851-A1 | GUANIDINE DERIVATIVES USEFUL IN THERAPY | Astra Aktiebolag (SE) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994021621-A1 | GUANIDINE DERIVATIVES USEFUL IN THERAPY | ASTRA AKTIEBOLAG (SE) | 1994-09-29 | — | — | WO | disclosed |
| EP-0248586-B1 | PROCESS FOR PRODUCING AMIDINE SULFONIC ACID INTERMEDIATES FOR GUANIDINES | McNeilab, Inc. (US) | 1993-08-25 | — | — | EP | disclosed |
| EP-0248586-A2 | Process for producing amidine sulfonic acid intermediates for guanidines | McNeilab, Inc. (US) | 1987-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242616-A1 | Derivatives of morphine-like opioid compounds | OPRM1, OPRK1, OPRD1 | NOX1 2971/4885MAPT 80/4885GAA 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.